Literature DB >> 23499560

Therapeutic benefits of 9-amino acid peptide derived from prothymosin alpha against ischemic damages.

Sebok Kumar Halder1, Junya Sugimoto, Hayato Matsunaga, Hiroshi Ueda.   

Abstract

Prothymosin alpha (ProTα), a nuclear protein, plays multiple functions including cell survival. Most recently, we demonstrated that the active 30-amino acid peptide sequence/P30 (amino acids 49-78) in ProTα retains its substantial activity in neuroprotection in vitro and in vivo as well as in the inhibition of cerebral blood vessel damages by the ischemic stress in retina and brain. But, it has remained to identify the minimum peptide sequence in ProTα that retains neuroprotective activity. The present study using the experiments of alanine scanning suggested that any amino acid in 9-amino acid peptide sequence/P9 (amino acids 52-60) of P30 peptide is necessary for its survival activity of cultured rat cortical neurons against the ischemic stress. In the retinal ischemia-perfusion model, intravitreous injection of P9 24h after ischemia significantly inhibited the cellular and functional damages at day 7. On the other hand, 2,3,5-triphenyltetrazolium chloride (TTC) staining and electroretinogram assessment showed that systemic delivery with P9 1h after the cerebral ischemia (1h tMCAO) significantly blocks the ischemia-induced brain damages. In addition, systemic P9 delivery markedly inhibited the cerebral ischemia (tMCAO)-induced disruption of blood vessels in brain. Taken together, the present study provides a therapeutic importance of 9-amino acid peptide sequence against ischemic damages.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499560     DOI: 10.1016/j.peptides.2013.02.022

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Potential Therapeutic Effects of Mi-Jian-Chang-Pu Decoction on Neurochemical and Metabolic Changes of Cerebral Ischemia-Reperfusion Injury in Rats.

Authors:  Jingjing Liu; Lingling Yang; Yang Niu; Chao Su; Yingli Wang; Ruru Ren; Jianyu Chen; Xueqin Ma
Journal:  Oxid Med Cell Longev       Date:  2022-05-06       Impact factor: 6.543

Review 2.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

3.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.